SecureCHEK AI

Founded: 2021
Enterprise Software, SaaS / RegTech, MarTech, Life Sciences, Compliance
3-5 employees
Stage: In the Market
SecureCHEK AI revolutionizes marketing for Life Sciences companies by using AI to efficiently expedite review of regulated materials to impact sales sooner. Our proven, practical software eliminates bottlenecks that limit productivity & marketing impact. Our system dramatically cuts time spent by essential internal medical, legal, and regulatory reviewers that must approve materials prior to distribution. This is key as the longer materials take to get approved, the more client-side resources are expended and agency hours charged at a time when pharma and med device companies can’t afford to have a negative effect on sales and the bottom line. SecureCHEK AI uses a unique combination of Analytical AI and GenAI to automate compliance reviews required for regulated marketing materials. Our differentiating technology stack delivers superior accuracy, verifiability and auditability versus GenAI-only software solutions that risk hallucinations and inaccuracy. Our prechecking tool analyzes new content in real-time, flagging errors/omissions. The easy-to-use Review Readiness Score instantly provides a detailed analysis of errors contained in the working document and instructions for how to correct them. Now materials are considered “review ready” and can be submitted for review, shortening review cycles from months to weeks.
Company Contacts
Address:

21B - 303 E 57 street

New York, NY

US 10022

Website URL:
Contact Us:
(203) 249-8115
Connect With Us
Contact Person

Important Disclosure: MedStartr.com is a website owned and operated by MedStartr, Inc., which is not a broker-dealer, funding portal or investment advisor; and neither the website nor MedStartr, Inc. participate in the offer or sale of securities. All securities related activity is conducted through Young America Capital, LLC, a registered broker-dealer and member of FINRA/SIPC. No communication, through this website, email or in any other medium, should be construed as a recommendation for any securities offering.